| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6119945 | Journal of Clinical Virology | 2015 | 5 Pages |
Abstract
In patients receiving first generation protease inhibitors, genotype SLC28A2 rs11854484 predicts CSA, and helps to identify a subgroup of patients with better tolerance of triple therapy.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Javier Ampuero, José Antonio Del Campo, Lourdes Rojas, José Luis Calleja, JoaquÃn Cabezas, Sabela Lens, Javier Crespo, Xavier Forns, Raúl J. Andrade, Inmaculada Fernández, MarÃa Buti, Raquel Millán, Manuel Romero-Gómez,